Christiane Auray-Blais

Last updated

Christiane Auray-Blais (born March 5, 1950) is a Canadian biochemist and professor specializing in preventive genetic medicine and mass spectrometry. [1] She is known for her work in neonatal screening of inherited metabolic diseases using urine specimen as a non-invasive biological matrix for the early identification of newborns with rare treatable diseases. [2] Currently, she serves as a professor in the Medical Genetics Division within the Department of Pediatrics at the Faculty of Medicine and Health Sciences at the Université de Sherbrooke. [3]

Contents

Education

She studied at the Faculty of Science at the Université de Sherbrooke, where she earned a bachelor's degree in biochemistry-physiology (B.Sc.) in 1972. [4]

She later obtained a master's degree in Health Law (LL.M.) from the Faculty of Law at the Université de Sherbrooke in 1998. [5]

She earned a Ph.D. in radiobiology from the Faculty of Medicine and Health Sciences of the Université de Sherbrooke in 2007. [6]

Following her doctoral studies, she pursued postdoctoral research at Duke University Medical Center in North Carolina under the guidance of David S. Millington in 2008. [7]

Career

Since May 1, 1972, she took on the role of biochemist-in-charge for the Provincial Neonatal Urine Screening Program for Hereditary Metabolic Diseases in Sherbrooke, Quebec, collaborating with Bernard Lemieux and Dennis Shapcott, she played a role in developing and validating the methodology to screen newborns in Quebec for inborn errors of metabolism in urine as part of the Quebec Network of Genetic Medicine. [8]

Currently, she serves as a full professor in the Medical Genetics Division within the Department of Pediatrics at the Faculty of Medicine and Health Sciences at the Université de Sherbrooke. [9] Auray-Blais has established collaborative partnerships to advance mass spectrometry in the clinical field in Sherbrooke, these partnerships have facilitated research into biomarkers for various diseases, including lysosomal diseases, Parkinson's disease, autism, asthma, cystic fibrosis, and vitamin B12 deficiency in the elderly, as well as several inborn errors of metabolism in newborns. [7]

Auray-Blais is the Scientific Director of the Waters-CHUS Expertise Centre in Clinical Mass Spectrometry and Director of the Waters Innovation Centre in Sherbrooke. [10] Additionally, she is a researcher at the Clinical Research Centre-CHUS in Sherbrooke, focusing on the mother-child axis. [11]

Her research has been published in peer-reviewed academic journals, including Science, Nature Communications, Analytical Chemistry, and the Journal of Clinical Investigation. [1]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Phenylketonuria</span> Amino acid metabolic disorder

Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. A baby born to a mother who has poorly treated PKU may have heart problems, a small head, and low birth weight.

<span class="mw-page-title-main">Neonatal heel prick</span> Blood collection procedure for newborns

The neonatal heel prick is a blood collection procedure done on newborns. It consists of making a pinprick puncture in one heel of the newborn to collect their blood. This technique is used frequently as the main way to collect blood from neonates. Other techniques include venous or arterial needle sticks, cord blood sampling, or umbilical line collection. This technique is often utilized for the Guthrie test, where it is used to soak the blood into pre-printed collection cards known as Guthrie cards.

<span class="mw-page-title-main">Université de Sherbrooke</span> University in Sherbrooke, Quebec, Canada

The Université de Sherbrooke is a French-language public research university in Sherbrooke, Quebec, Canada, with a second campus in Longueuil, a suburb on the South Shore of Montreal. It is one of two universities in the Estrie region of Quebec, and the only French-language university for the region.

<span class="mw-page-title-main">Medium-chain acyl-coenzyme A dehydrogenase deficiency</span> Medical condition

Medium-chain acyl-CoA dehydrogenase deficiency is a disorder of fatty acid oxidation that impairs the body's ability to break down medium-chain fatty acids into acetyl-CoA. The disorder is characterized by hypoglycemia and sudden death without timely intervention, most often brought on by periods of fasting or vomiting.

<span class="mw-page-title-main">Newborn screening</span> Practice of testing infants for diseases

Newborn screening (NBS) is a public health program of screening in infants shortly after birth for conditions that are treatable, but not clinically evident in the newborn period. The goal is to identify infants at risk for these conditions early enough to confirm the diagnosis and provide intervention that will alter the clinical course of the disease and prevent or ameliorate the clinical manifestations. NBS started with the discovery that the amino acid disorder phenylketonuria (PKU) could be treated by dietary adjustment, and that early intervention was required for the best outcome. Infants with PKU appear normal at birth, but are unable to metabolize the essential amino acid phenylalanine, resulting in irreversible intellectual disability. In the 1960s, Robert Guthrie developed a simple method using a bacterial inhibition assay that could detect high levels of phenylalanine in blood shortly after a baby was born. Guthrie also pioneered the collection of blood on filter paper which could be easily transported, recognizing the need for a simple system if the screening was going to be done on a large scale. Newborn screening around the world is still done using similar filter paper. NBS was first introduced as a public health program in the United States in the early 1960s, and has expanded to countries around the world.

Inborn errors of metabolism form a large class of genetic diseases involving congenital disorders of enzyme activities. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or due to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are often referred to as congenital metabolic diseases or inherited metabolic disorders. Another term used to describe these disorders is "enzymopathies". This term was created following the study of biodynamic enzymology, a science based on the study of the enzymes and their products. Finally, inborn errors of metabolism were studied for the first time by British physician Archibald Garrod (1857–1936), in 1908. He is known for work that prefigured the "one gene-one enzyme" hypothesis, based on his studies on the nature and inheritance of alkaptonuria. His seminal text, Inborn Errors of Metabolism, was published in 1923.

<span class="mw-page-title-main">Isovaleric acidemia</span> Medical condition disrupting normal metabolism

Isovaleric acidemia is a rare autosomal recessive metabolic disorder which disrupts or prevents normal metabolism of the branched-chain amino acid leucine. It is a classical type of organic acidemia.

<span class="mw-page-title-main">Maple syrup urine disease</span> Autosomal recessive metabolic disorder

Maple syrup urine disease (MSUD) is an autosomal recessive metabolic disorder affecting branched-chain amino acids. It is one type of organic acidemia. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax, particularly prior to diagnosis and during times of acute illness. It was described by John Menkes in the 1950s.

<span class="mw-page-title-main">Systemic primary carnitine deficiency</span> Medical condition

Systemic primary carnitine deficiency (SPCD) is an inborn error of fatty acid transport caused by a defect in the transporter responsible for moving carnitine across the plasma membrane. Carnitine is an important amino acid for fatty acid metabolism. When carnitine cannot be transported into tissues, fatty acid oxidation is impaired, leading to a variety of symptoms such as chronic muscle weakness, cardiomyopathy, hypoglycemia and liver dysfunction. The specific transporter involved with SPCD is OCTN2, coded for by the SLC22A5 gene located on chromosome 5. SPCD is inherited in an autosomal recessive manner, with mutated alleles coming from both parents.

<span class="mw-page-title-main">Michael H. Gelb</span>

Professor Michael H. Gleb is an American biochemist and chemist specializing in enzymes and particularly those of medical significance. He is the Boris and Barbara L. Weinstein Endowed Chair in Chemistry at the University of Washington in Seattle. He also teaches Honors Organic Chemistry, Chemical Biology and Enzymology.

<span class="mw-page-title-main">Group B streptococcal infection</span> Medical condition

Group B streptococcal infection, also known as Group B streptococcal disease or just Group B strep infection, is the infectious disease caused by the bacterium Streptococcus agalactiae, which is the most common human pathogen belonging to the group B of the Lancefield classification of streptococci—hence the group B stretococcal (GBS) infection nomenclature. Infection with GBS can cause serious illness and sometimes death, especially in newborns, the elderly, and people with compromised immune systems. The most severe form of group B streptococcal disease is neonatal meningitis in infants, which is frequently lethal and can cause permanent neuro-cognitive impairment.

<span class="mw-page-title-main">Argininosuccinic aciduria</span> Medical condition

Argininosuccinic aciduria is an inherited disorder that causes the accumulation of argininosuccinic acid in the blood and urine. Some patients may also have an elevation of ammonia, a toxic chemical, which can affect the nervous system. Argininosuccinic aciduria may become evident in the first few days of life because of high blood ammonia, or later in life presenting with "sparse" or "brittle" hair, developmental delay, and tremors.

<span class="mw-page-title-main">3-Methylcrotonyl-CoA carboxylase deficiency</span> Medical condition

3-Methylcrotonyl-CoA carboxylase deficiency also known as 3-Methylcrotonylglycinuria is an inborn error of leucine metabolism and is inherited through an autosomal recessive fashion. 3-Methylcrotonyl-CoA carboxylase deficiency is caused by mutations in the MCCC1 gene, formerly known as MMCA, or the MCCC2 gene, formerly known as MCCB. MCCC1 encodes the a-subunits of 3-methylcrotonyl-CoA carboxylase while MCCC2 encodes the b-subunits. The clinical presentation of 3-Methylcrotonyl-CoA carboxylase deficiency is varied, even within members of the same family.

<span class="mw-page-title-main">Histidinemia</span> Histidine metabolism disease that involves a deficiency of the enzyme histidase

Histidinemia is a rare autosomal recessive metabolic disorder caused by a deficiency of the enzyme histidase. Histidase is needed for the metabolism of the amino acid histidine. Although originally thought to be linked to multiple developmental disorders histidinemia is now accepted as a relatively benign disorder, leading to a reduction in the prevalence of neonatal screening procedures.

<span class="mw-page-title-main">Guanidinoacetate methyltransferase deficiency</span> Medical condition

Guanidinoacetate methyltransferase deficiency is an autosomal recessive cerebral creatine deficiency that primarily affects the nervous system and muscles. It is the first described disorder of creatine metabolism, and results from deficient activity of guanidinoacetate methyltransferase, an enzyme involved in the synthesis of creatine. Clinically, affected individuals often present with hypotonia, seizures and developmental delay. Diagnosis can be suspected on clinical findings, and confirmed by specific biochemical tests, brain magnetic resonance spectroscopy, or genetic testing. Biallelic pathogenic variants in GAMT are the underlying cause of the disorder. After GAMT deficiency is diagnosed, it can be treated by dietary adjustments, including supplementation with creatine. Treatment is highly effective if started early in life. If treatment is started late, it cannot reverse brain damage which has already taken place.

Organic acidemia is a term used to classify a group of metabolic disorders which disrupt normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids which are usually not present.

Neonatal sepsis is a type of neonatal infection and specifically refers to the presence in a newborn baby of a bacterial blood stream infection (BSI) in the setting of fever. Older textbooks may refer to neonatal sepsis as "sepsis neonatorum". Criteria with regards to hemodynamic compromise or respiratory failure are not useful clinically because these symptoms often do not arise in neonates until death is imminent and unpreventable. Neonatal sepsis is divided into two categories: early-onset sepsis (EOS) and late-onset sepsis (LOS). EOS refers to sepsis presenting in the first 7 days of life, with LOS referring to presentation of sepsis after 7 days. Neonatal sepsis is the single most common cause of neonatal death in hospital as well as community in developing country.

Anne Monique Nuyt is a Canadian paediatrician who is Professor of Neonatology and Canada Research Chair in Prematurity and Developmental Origins of Cardiovascular Health and Diseases at the Université de Montréal. Her research considers how perinatal oxidative stress can alter the structural development and function of the cardiovascular system.

Combined malonic and methylmalonic aciduria (CMAMMA), also called combined malonic and methylmalonic acidemia is an inherited metabolic disease characterized by elevated levels of malonic acid and methylmalonic acid. However, the methylmalonic acid levels exceed those of malonic acid. CMAMMA is not only an organic aciduria but also a defect of mitochondrial fatty acid synthesis (mtFASII). Some researchers have hypothesized that CMAMMA might be one of the most common forms of methylmalonic acidemia, and possibly one of the most common inborn errors of metabolism. Due to being infrequently diagnosed, it most often goes undetected.

<span class="mw-page-title-main">Louis Isaac Woolf</span> British biochemist (1919–2021)

Louis Isaac Woolf was a British biochemist who played a crucial role in the early detection and the treatment of phenylketonuria (PKU).

References

  1. 1 2 Vallée, Pierre (2013-04-20). "Centre hospitalier universitaire de l'Université de Sherbrooke - De nouveaux biomarqueurs pour la maladie de Fabry". Le Devoir (in French). Retrieved 2024-05-22.
  2. Jacques, Dany (2010-10-07). "Un prix médical pour la Dre Christiane Auray-Blais". Le Progrès de Coaticook (in French). Retrieved 2024-05-22.
  3. "Découverte de nouveaux biomarqueurs pour dépister les patients atteints de la maladie de Fabry présentant une variante cardiaque". Université de Sherbrooke (in Canadian French). Retrieved 2024-05-22.
  4. "Christiane Auray - Spécialistes - Recherche - Université de Sherbrooke". www.usherbrooke.ca. Retrieved 2024-05-22.
  5. "Christiane Auray-Blais - Biochemist, Professor, Researcher, Quebec, Canada | eMedEvents". www.emedevents.com. Retrieved 2024-05-22.
  6. "WSEAS". www.wseas.org. Retrieved 2024-05-22.
  7. 1 2 "Christiane Auray-Blais, LLM, PhD | Parkinson's Disease". www.michaeljfox.org. Retrieved 2024-05-22.
  8. Chatel, Sylviane (2023-11-16). "Parents, savez-vous où vont les échantillons d'urine de votre nouveau-né ?". Fondation de la recherche pédiatrique (in Canadian French). Retrieved 2024-05-22.
  9. "Plus que jamais vers un traitement pour la maladie de Fabry". Université de Sherbrooke (in Canadian French). Retrieved 2024-05-22.
  10. "New centre of excellence for mass spectrometry | Canadian Healthcare Technology" . Retrieved 2024-05-22.
  11. "CIUSSS de l'Estrie-CHUS inaugurates Waters Centre of Innovation for Mass Spectrometry". Sherbrooke Record. 2019-05-01. Retrieved 2024-05-22.

[[authority control}}